Delivery of muscle relaxants through an inhalation route
First Claim
1. A method of treating musculoskeletal pain or restless leg syndrome comprising administering a therapeutic amount of a muscle relaxant condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% muscle relaxant degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of muscle relaxants through an inhalation route. Specifically, it relates to aerosols containing muscle relaxants that are used in inhalation therapy. In a method aspect of the present invention, a muscle relaxant is delivered to a patient through an inhalation route. The method comprises: a) heating a coating of a muscle relaxant, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% muscle relaxant degradation products. In a kit aspect of the present invention, a kit for delivering a muscle relaxant through an inhalation route is provided which comprises: a) a coating of a muscle relaxant and b) a device for dispensing said coating a muscle relaxant as a condensation aerosol.
88 Citations
25 Claims
-
1. A method of treating musculoskeletal pain or restless leg syndrome comprising administering a therapeutic amount of a muscle relaxant condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% muscle relaxant degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
11. A method of treating musculoskeletal pain or restless leg syndrome comprising administering a therapeutic amount of a quinine, chlorzoxazone, carisprodol or cyclobenzaprine condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% quinine, chlorzoxazone, carisprodol or cyclobenzaprine degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (12, 13, 14)
-
15. A method of administering a muscle relaxant to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of a muscle relaxant having less than 5% muscle relaxant degradation products and an MMAD less than 3 microns wherein the peak plasma concentration of the muscle relaxant is achieved in less than 0.1 hours.
-
16. A method of administering quinine, chlorzoxazone, carisprodol or cyclobenzaprine to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of quinine, chlorzoxazone, carisprodol or cyclobenzaprine having less than 5% quinine, chlorzoxazone, carisprodol or cyclobenzaprine degradation products and an MMAD less than 3 microns wherein the peak plasma drug concentration of quinine, chlorzoxazone, carisprodol or cyclobenzaprine is achieved in less than 0.1 hours.
-
17. A kit for delivering a drug aerosol comprising:
-
a) a coating of a muscle relaxant composition and b) a device for dispensing said coating as a condensation aerosol. - View Dependent Claims (18, 19, 20, 21, 22, 23, 24, 25)
-
Specification